ghk-cu fda approved status approval injectable GHK-Cu Side Effects: What Does the Research Say? Doctor Explains Is GHK-Cu FDA Approved? Regulatory
Description
Originally developed as a treatment for Type 2 diabetes, Semaglutide has been FDA-approved for weight loss in individuals with obesity
At minimum: Outcomes Weight trend (weekly average) Waist circumference Body composition if available (DEXA, BIA with consistency) Strength markers (basic lifts, grip strength, functional tests) Safety Blood pressure + resting HR A1c and fasting glucose (more often if diabetes) CMP (liver/kidney) Lipids (periodic) If manipulating GH/IGF-1 signaling: IGF-1 (and clinical context matters) Stop criteria Persistent tachycardia, edema, severe fatigue, worsening glycemia, abnormal labs, or new symptoms you cant explain The what to ask your clinic questions (high signal, low fluff) If a clinic recommends a peptide stack, ask: What is the problem were solving, in one sentence

Those taking tirzepatide (as opposed to a placebo) were far less likely to develop type 2 diabetes

12:301:30 pm CDT IcoSema 815-P CGM-Derived Model-Based Postprandial Glucose with IcoSema vs
